HAIFA, Israel, July 8 /PRNewswire/ -- Elscint Ltd. (NYSE: ELT), a
subsidiary of Elbit Medical Imaging Ltd. (Nasdaq: EMITF), announced today that
contrary to a recent article published in the Israeli newspaper "Globes," the
Company has not considered discontinuing its MRI product line.
Elscint's MRI orders in the second quarter of 1998 increased more than 20%
compared to the first quarter, attributable primarily to solid market
reception to the Company's new Prima 1TG MRI. In late 1996, Elscint reported
that it had developed the revolutionary Prima 1TG, 1.0 Tesla System, which
uses unique Twin-Gradient(TM) technology for better imaging features. This
system received FDA clearance in June 1997 and began commercial deliveries
last month following evaluation of the system in beta-sites in Europe.
Elscint is an advanced medical imaging company serving healthcare
professionals worldwide. Guided by the philosophy of applying unique
technologies for the advancement of cost-effective healthcare, Elscint
designs, manufactures, sells and services a wide range of sophisticated
computer-based medical imaging products including Computerized Tomography
(CT), Magnetic Resonance Imaging (MRI), Nuclear Medicine (NM) and Mammography
systems.
This release contains certain forward-looking statements which involve
known and unknown risks, uncertainties or other factors not under the
Company's control which may cause actual results, performance or achievements
of the Company to be materially different from the results, performance or
other expectations implied by these forward-looking statements. These factors
include, but are not limited to, those detailed in the Company's periodic
filings with the Securities and Exchange Commission.
SOURCE Elscint Ltd.
 back to top
Related links:
http://www.elscint.co.il
CONTACT:
Gabi Yankovitz, VP, Finance & CFO of Elscint,
972-4-8310271; or Laurie Berman, General Info., 310-442-0599, or
Alicia Nieva-Woodgate, Media Info., or Brian Gill, Investor
Info., 212-661-8030, all of The Financial Relations Board
NOTE TO EDITORS: For further information on Elscint, via
facsimile at no cost, please call 1-800-PRO-INFO and enter
company code 206 or ticker symbol ELT.
|
